TY  - GEN
AU  - El-Khoueiry,A B
AU  - Ramanathan,R K
AU  - Yang,D Y
AU  - Zhang,W
AU  - Shibata,S
AU  - Wright,J J
AU  - Gandara,D
AU  - Lenz,H J
TI  - A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
SN  - 1573-0646
PY  - 2012///0920
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Benzenesulfonates
KW  - administration & dosage
KW  - Cyclooxygenase 2
KW  - genetics
KW  - Cytidine Deaminase
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Niacinamide
KW  - analogs & derivatives
KW  - Nucleoside Deaminases
KW  - Pancreatic Neoplasms
KW  - drug therapy
KW  - Phenylurea Compounds
KW  - Polymorphism, Single Nucleotide
KW  - Pyridines
KW  - Ribonucleoside Diphosphate Reductase
KW  - Sorafenib
KW  - Tumor Suppressor Proteins
KW  - Gemcitabine
N1  - Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1007/s10637-011-9658-9
ER  -